Engaging Our Shareholders: Pfizer Announces New Chief Investor Relations Officer

Consistent with its commitment to drive shareholder value, Pfizer announced Wednesday that Francesca DeMartino will join the company as the Chief Investor Relations Officer effective Oct. 2.

In her new role, DeMartino will communicate with the shareholder community about Pfizer’s innovation and growth initiatives while updating investors on progress on our strategy and the goals the company has set to change patients’ lives and deliver shareholder value. She will also advise Pfizer’s leaders on investor relations and capital markets strategies and report to Chief Corporate Affairs Officer and Executive Vice President Sally Susman.

A Quarter Century of Experience

DeMartino brings to the role nearly 25 years of experience in investor relations, communications and corporate finance for healthcare companies, most recently as the senior vice president of investor relations at Becton Dickinson. Prior to that, she served as Vice President, Investor Relations at Medtronic. During her tenure at Medtronic, the company was recognized by IR Magazine for Best Overall Investor Relations and Best Investor Relations in Healthcare. She has also previously held leadership roles in investor relations at the biotechnology company Macrocure, and OMRIX Biopharmaceuticals, and in communications at Johnson & Johnson, among other posts.

She joins Pfizer as the company is progressing towards its goal of launching 19 new products and indications in 18 months. During the first six months of 2023, Pfizer returned capital directly to shareholders through $4.6 billion of cash dividends while reaching more than 350 million patients around the world with its medicines and vaccines.^[1] These efforts, combined with the potential closing of our proposed acquisition of Seagen in the coming months, pending regulatory approval, makes this an exciting time for Pfizer.

Transition Through 2023

The New York-based DeMartino is a leader for Advancing Women Executives (AWE) and a member of the senior executive women’s network CHIEF. She is a founding board member for the CSNK2A1 Foundation, which is focused on finding a cure for the ultra-rare genetic disorder called Okur-Chung Neurodevelopmental Syndrome.

DiMartino has a Bachelor of Arts in international and area studies from the University of California, Berkeley, and a minor in business administration from the Walter A. Haas School of Business.

Chris Stevo, Pfizer’s current Investor Relations lead will work with DeMartino and the corporate affairs and finance teams to ensure a successful transition through the end of 2023. During the past two years, Stevo has broadened outreach from Pfizer’s investor relations department and brought extensive knowledge of the healthcare industry to the company. He is leaving to pursue external opportunities.

[1] The Patients Treated metric is calculated from Pfizer and third-party datasets. Figures may be limited given the coverage provided by external sources (e.g., calendar duration, geographic and product coverage). Numbers are estimates and in some cases use global volume, daily dosage and number of treatment days to facilitate calculations. Methodologies to calculate estimates may vary by product type given the nature of the product and available data. Patients taking multiple Pfizer products may be counted as multiple patients towards total. Numbers include estimated patient counts from U.S. Patient Assistance Programs, ex-U.S. access & affordability programs, product donations and Global Commercial Access Partnerships (this does not include An Accord for a Healthier World). Historical estimates may periodically be subject to revision due to restatements in the underlying data source.

Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.